News Valeant sells female libido drug back to former owners Valeant has sold its controversial female libido drug to former shareholders in Sprout, the company that first developed it before a $1 billion buyout two years ago.
News 'Trust gap' is holding back AI in healthcare The potential for AI to help tackle bottlenecks in healthcare is being held back by patient scepticism and doctor concerns about bias and liability.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
